China-based Sinovac Biotech Ltd (NASDAQ: SVA) has announced a strategic partnership with Bogota, the capital of Colombia, to establish a joint venture named BogotáBio. The collaboration aims to strengthen local manufacturing capabilities for multiple vaccines and enhance novel vaccine research and development within the country. Colombia was one of the first nations to adopt Sinovac’s inactivated SARS-CoV-2 vaccine, CoronaVac, during the pandemic.
Expanding Vaccine Pre-Certification and Emergency Use
Sinovac boasts a robust portfolio of vaccines, with four that have either passed the pre-certification of the World Health Organization (WHO) or are on the emergency use list. These include the hepatitis A virus (HVA) inactivated vaccine, Sabin strain polio inactivated vaccine, and varicella attenuated live vaccine, along with the inactivated COVID-19 vaccine. The establishment of BogotáBio is a significant step in Sinovac’s global expansion strategy, aiming to improve access to vaccines and contribute to public health initiatives in Colombia and potentially other regions.-Fineline Info & Tech
